Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer
Indian Journal of Pharmacology · 2026-11 · 58 (6) · 773-783
DOI: 10.4103/ijp.ijp_224_26 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Pharmacology, online erschienen am 02.11.2026. Verfasst von Mohamed Saad Saad Younis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Hauptthemen laut MEDLINE: Cisplatin, Antineoplastic Agents, Head and Neck Neoplasms, Protective Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: This study seeks to evaluate the safety and efficacy of magnesium (MgSO 4 ) as a protective agent against cisplatin-induced nephrotoxicity (CIN) in cases with head and neck cancers (HNC). METHODS: One-hundred newly diagnosed squamous cell carcinoma HNC were randomly allocated into 4 groups: 25 cases in each. Group 1 (control group) received cisplatin 40 mg/m 2 for 7 cycles (each cycle is 1 week). Group 2 received cisplatin 40 mg/m 2 and 1 g of parenteral MgSO 4 intravenous infusion (IVI) for 7 cycles. Group 3 received cisplatin 40 mg/m 2 and 2 g of parenteral MgSO 4 IVI for 7 cycles. Group 4 received cisplatin 40 mg/m 2 and 3 g of parenteral MgSO 4 for 7 cycles. All four groups received radiotherapy concurrent with cisplatin for 7 cycles. RESULTS: The groups containing Mg IVI as (MgSO 4 ) had a significant improvement (lower level) in Urine kidney injury molecule-1 (KIM-1) and Urine Neutrophil gelatinase associated lipocalin (NGAL) than Group I (control group) ( P < 0.05). Serum soluble Fas ligand (sFasL) and Malondialdehyde (MDA) after the end cycle (7 cycle) was significantly decreased in Group IV than group I (control group) ( P < 0.05), MgSo 4 was significantly decreased in Group IV (3 g Mg) than Group III (2 g Mg) ( P < 0.001) and Group II (1 g Mg). CONCLUSIONS: Mg can serve as a protective agent against CIN, as it reduces renal injury biomarkers, including urinary KIM-1, urinary NGAL, serum sFasL, and serum MDA when incorporated into treatment regimens at different doses, compared to cisplatin alone. Moreover, Mg had a promising role in the improvement of quality of life in cases with HNC receiving cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Department of Clinical Oncology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Zitieren
APA
Younis, M. S. S., El-Shebiny, M. A., & El-Haggar, S. M. (2026). Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer. Indian Journal of Pharmacology, 58(6), 773-783. https://doi.org/10.4103/ijp.ijp_224_26
Vancouver
Younis MSS, El-Shebiny MA, El-Haggar SM. Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer. Indian Journal of Pharmacology. 2026;58(6):773-783. doi:10.4103/ijp.ijp_224_26
BibTeX
@article{Younis2026,
author = {Younis, Mohamed Saad Saad and El-Shebiny, Mohamed Abdo and El-Haggar, Sahar Mohamed},
title = {Role of magnesium as a protective agent in cisplatin-induced nephrotoxicity in head and neck cancer},
journal = {Indian Journal of Pharmacology},
year = {2026},
volume = {58},
number = {6},
pages = {773--783},
doi = {10.4103/ijp.ijp_224_26}
}
EUVIMED